{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T06:25:35Z","timestamp":1790835935650,"version":"4.1.0"},"reference-count":122,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2014,6,1]],"date-time":"2014-06-01T00:00:00Z","timestamp":1401580800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2014,6,1]],"date-time":"2014-06-01T00:00:00Z","timestamp":1401580800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100003478","name":"Ministry of Health, Labour and Welfare","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003478","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001700","name":"Ministry of Education, Culture, Sports, Science and Technology","doi-asserted-by":"publisher","award":["24659599"],"award-info":[{"award-number":["24659599"]}],"id":[{"id":"10.13039\/501100001700","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Surgical Oncology"],"published-print":{"date-parts":[[2014,6]]},"DOI":"10.1016\/j.suronc.2014.03.004","type":"journal-article","created":{"date-parts":[[2014,3,27]],"date-time":"2014-03-27T07:15:12Z","timestamp":1395904512000},"page":"99-106","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":38,"title":["Intraperitoneal chemotherapy against peritoneal carcinomatosis"],"prefix":"10.1016","volume":"23","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4075-1795","authenticated-orcid":false,"given":"Joji","family":"Kitayama","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.suronc.2014.03.004_bib1","first-page":"1131","article-title":"Surgical treatment for peritoneal carcinomatosis from gastric cancer","volume":"36","author":"Yonemura","year":"2010","journal-title":"Eur J Surg Oncol \u2013 J Eur Soc Surg Oncol Br Assoc Surg Oncol"},{"key":"10.1016\/j.suronc.2014.03.004_bib2","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/j.critrevonc.2006.03.004","article-title":"Ovarian cancer","volume":"60","author":"Colombo","year":"2006","journal-title":"Crit Rev Oncol Hematol"},{"key":"10.1016\/j.suronc.2014.03.004_bib3","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1002\/(SICI)1097-0142(20000115)88:2<358::AID-CNCR16>3.0.CO;2-O","article-title":"Peritoneal carcinomatosis from non-gynecologic malignancies: results of the EVOCAPE 1 multicentric prospective study","volume":"88","author":"Sadeghi","year":"2000","journal-title":"Cancer"},{"key":"10.1016\/j.suronc.2014.03.004_bib4","doi-asserted-by":"crossref","first-page":"1637","DOI":"10.1007\/s00432-009-0667-4","article-title":"Intraoperative hyperthermic intraperitoneal chemotherapy after cytoreductive surgery in ovarian cancer peritoneal carcinomatosis: systematic review of current results","volume":"135","author":"Chua","year":"2009","journal-title":"J\u00a0Cancer Res Clin Oncol"},{"key":"10.1016\/j.suronc.2014.03.004_bib5","doi-asserted-by":"crossref","first-page":"4011","DOI":"10.1200\/JCO.2006.07.1142","article-title":"Systematic review on the efficacy of cytoreductive surgery combined with perioperative intraperitoneal chemotherapy for peritoneal carcinomatosis from colorectal carcinoma","volume":"24","author":"Yan","year":"2006","journal-title":"J\u00a0Clin Oncol \u2013 Off J Am Soc Clin Oncol"},{"key":"10.1016\/j.suronc.2014.03.004_bib6","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1007\/978-1-4613-1247-5_4","article-title":"Peritoneal-plasma barrier","volume":"82","author":"Jacquet","year":"1996","journal-title":"Cancer Treat Res"},{"key":"10.1016\/j.suronc.2014.03.004_bib7","doi-asserted-by":"crossref","first-page":"988","DOI":"10.1200\/JCO.2005.05.2456","article-title":"Intraperitoneal chemotherapy of ovarian cancer: a review, with a focus on practical aspects of treatment","volume":"24","author":"Markman","year":"2006","journal-title":"J\u00a0Clin Oncol \u2013 Off J Am Soc Clin Oncol"},{"key":"10.1016\/j.suronc.2014.03.004_bib8","first-page":"802","article-title":"Multimodal treatment approaches for peritoneal carcinosis in colorectal cancer","volume":"108","author":"Piso","year":"2011","journal-title":"Dtsch Arztebl Int"},{"key":"10.1016\/j.suronc.2014.03.004_bib9","doi-asserted-by":"crossref","first-page":"2449","DOI":"10.1200\/JCO.2011.39.7166","article-title":"Early- and long-term outcome data of patients with pseudomyxoma peritonei from appendiceal origin treated by a strategy of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy","volume":"30","author":"Chua","year":"2012","journal-title":"J\u00a0Clin Oncol \u2013 Off J Am Soc Clin Oncol"},{"key":"10.1016\/j.suronc.2014.03.004_bib10","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1016\/j.soc.2012.07.010","article-title":"Peritoneal mesothelioma: current status and future directions","volume":"21","author":"Chua","year":"2012","journal-title":"Surg Oncol Clin N Am"},{"key":"10.1016\/j.suronc.2014.03.004_bib11","first-page":"1","article-title":"Pharmacokinetic rationale for peritoneal drug administration in the treatment of ovarian cancer","volume":"62","author":"Dedrick","year":"1978","journal-title":"Cancer Treat Rep"},{"key":"10.1016\/j.suronc.2014.03.004_bib12","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1016\/S1470-2045(03)01074-X","article-title":"Intraperitoneal antineoplastic drug delivery: rationale and results","volume":"4","author":"Markman","year":"2003","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.suronc.2014.03.004_bib13","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1634\/theoncologist.10-2-112","article-title":"Update on chemotherapeutic agents utilized for perioperative intraperitoneal chemotherapy","volume":"10","author":"Sugarbaker","year":"2005","journal-title":"Oncologist"},{"issue":"Suppl.\u00a01","key":"10.1016\/j.suronc.2014.03.004_bib14","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1136\/ijgc-00009577-200505001-00002","article-title":"Treatment goals in ovarian cancer","volume":"15","author":"Ozols","year":"2005","journal-title":"Int J Gynecol Cancer"},{"key":"10.1016\/j.suronc.2014.03.004_bib15","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/0305-7372(86)90007-1","article-title":"Intraperitoneal antineoplastic agents for tumors principally confined to the peritoneal cavity","volume":"13","author":"Markman","year":"1986","journal-title":"Cancer Treat Rev"},{"key":"10.1016\/j.suronc.2014.03.004_bib16","doi-asserted-by":"crossref","first-page":"1950","DOI":"10.1056\/NEJM199612263352603","article-title":"Intraperitoneal cisplatin plus intravenous cyclophosphamide versus intravenous cisplatin plus intravenous cyclophosphamide for stage III ovarian cancer","volume":"335","author":"Alberts","year":"1996","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.suronc.2014.03.004_bib17","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1200\/JCO.2001.19.4.1001","volume":"19","author":"Markman","year":"2001","journal-title":"J\u00a0Clin Oncol \u2013 Off J Am Soc Clin Oncol"},{"key":"10.1016\/j.suronc.2014.03.004_bib18","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1056\/NEJMoa052985","article-title":"Intraperitoneal cisplatin and paclitaxel in ovarian cancer","volume":"354","author":"Armstrong","year":"2006","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.suronc.2014.03.004_bib19","doi-asserted-by":"crossref","first-page":"82","DOI":"10.6004\/jnccn.2011.0008","article-title":"Epithelial ovarian cancer","volume":"9","author":"Morgan","year":"2011","journal-title":"J\u00a0Natl Compr Canc Netw"},{"key":"10.1016\/j.suronc.2014.03.004_bib20","first-page":"4","article-title":"Advanced cytoreduction as surgical standard of care and hyperthermic intraperitoneal chemotherapy as promising treatment in epithelial ovarian cancer","volume":"37","author":"Deraco","year":"2011","journal-title":"Eur J Surg Oncol \u2013 J Eur Soc Surg Oncol Br Assoc Surg Oncol"},{"key":"10.1016\/j.suronc.2014.03.004_bib21","doi-asserted-by":"crossref","first-page":"1040","DOI":"10.1007\/s00268-004-7461-x","article-title":"Cytoreductive surgery and intraperitoneal chemohyperthermia for recurrent peritoneal carcinomatosis from ovarian cancer","volume":"28","author":"Zanon","year":"2004","journal-title":"World J Surg"},{"key":"10.1016\/j.suronc.2014.03.004_bib22","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1016\/j.ygyno.2004.05.044","article-title":"Effects of intraperitoneal hyperthermic chemotherapy in ovarian cancer","volume":"94","author":"Ryu","year":"2004","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.suronc.2014.03.004_bib23","first-page":"671","article-title":"Cytoreduction combined with intraperitoneal hyperthermic perfusion chemotherapy in advanced\/recurrent ovarian cancer patients: the experience of National Cancer Institute of Milan","volume":"32","author":"Raspagliesi","year":"2006","journal-title":"Eur J Surg Oncol \u2013 J Eur Soc Surg Oncol Br Assoc Surg Oncol"},{"key":"10.1016\/j.suronc.2014.03.004_bib24","doi-asserted-by":"crossref","first-page":"1813","DOI":"10.1007\/s00268-007-9146-8","article-title":"Cytoreductive surgery and intraperitoneal chemo-hyperthermia for chemo-resistant and recurrent advanced epithelial ovarian cancer: prospective study of 81 patients","volume":"31","author":"Cotte","year":"2007","journal-title":"World J Surg"},{"key":"10.1016\/j.suronc.2014.03.004_bib25","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1002\/cncr.23553","article-title":"Cytoreductive surgery (peritonectomy procedures) combined with hyperthermic intraperitoneal chemotherapy (HIPEC) in the treatment of diffuse peritoneal carcinomatosis from ovarian cancer","volume":"113","author":"Di Giorgio","year":"2008","journal-title":"Cancer"},{"key":"10.1016\/j.suronc.2014.03.004_bib26","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1186\/1477-7819-7-14","article-title":"Intra-operative intra-peritoneal chemotherapy with cisplatin in patients with peritoneal carcinomatosis of ovarian cancer","volume":"7","author":"Guardiola","year":"2009","journal-title":"World J Surg Oncol"},{"key":"10.1016\/j.suronc.2014.03.004_bib27","first-page":"1186","article-title":"Cytoreductive surgery and modified heated intraoperative intraperitoneal chemotherapy (HIPEC) for advanced and recurrent ovarian cancer \u2013 12-year single center experience","volume":"35","author":"Pavlov","year":"2009","journal-title":"Eur J Surg Oncol \u2013 J Eur Soc Surg Oncol Br Assoc Surg Oncol"},{"key":"10.1016\/j.suronc.2014.03.004_bib28","first-page":"358341","article-title":"Cytoreductive surgery combined with hyperthermic intraperitoneal intraoperative chemotherapy in the treatment of advanced epithelial ovarian cancer","volume":"2012","author":"Tentes","year":"2012","journal-title":"J\u00a0Oncol"},{"key":"10.1016\/j.suronc.2014.03.004_bib29","doi-asserted-by":"crossref","first-page":"4052","DOI":"10.1245\/s10434-012-2510-4","article-title":"Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC) for persistent and recurrent advanced ovarian carcinoma: a multicenter, prospective study of 246 patients","volume":"19","author":"Bakrin","year":"2012","journal-title":"Ann Surg Oncol"},{"key":"10.1016\/j.suronc.2014.03.004_bib30","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1002\/jso.20597","article-title":"Radical surgery-peritonectomy and intraoperative intraperitoneal chemotherapy for the treatment of peritoneal carcinomatosis in recurrent or primary ovarian cancer","volume":"94","author":"Rufian","year":"2006","journal-title":"J\u00a0Surg Oncol"},{"key":"10.1016\/j.suronc.2014.03.004_bib31","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/j.ygyno.2007.03.019","article-title":"Treatment of ovarian cancer with paclitaxel- or carboplatin-based intraperitoneal hyperthermic chemotherapy during secondary surgery","volume":"106","author":"Bae","year":"2007","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.suronc.2014.03.004_bib32","doi-asserted-by":"crossref","first-page":"e362","DOI":"10.1016\/S1470-2045(12)70210-3","article-title":"Cytoreductive surgery plus hyperthermic perioperative chemotherapy to treat peritoneal metastases from colorectal cancer: standard of care or an experimental approach?","volume":"13","author":"Sugarbaker","year":"2012","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.suronc.2014.03.004_bib33","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1007\/s10434-004-1167-z","article-title":"Long-term survival of peritoneal carcinomatosis of colorectal origin","volume":"12","author":"Verwaal","year":"2005","journal-title":"Ann Surg Oncol"},{"key":"10.1016\/j.suronc.2014.03.004_bib34","doi-asserted-by":"crossref","first-page":"3737","DOI":"10.1200\/JCO.2003.04.187","article-title":"Randomized trial of cytoreduction and hyperthermic intraperitoneal chemotherapy versus systemic chemotherapy and palliative surgery in patients with peritoneal carcinomatosis of colorectal cancer","volume":"21","author":"Verwaal","year":"2003","journal-title":"J\u00a0Clin Oncol \u2013 Off J Am Soc Clin Oncol"},{"key":"10.1016\/j.suronc.2014.03.004_bib35","doi-asserted-by":"crossref","first-page":"2426","DOI":"10.1245\/s10434-008-9966-2","article-title":"8-year follow-up of randomized trial: cytoreduction and hyperthermic intraperitoneal chemotherapy versus systemic chemotherapy in patients with peritoneal carcinomatosis of colorectal cancer","volume":"15","author":"Verwaal","year":"2008","journal-title":"Ann Surg Oncol"},{"key":"10.1016\/j.suronc.2014.03.004_bib36","doi-asserted-by":"crossref","first-page":"3284","DOI":"10.1200\/JCO.2004.10.012","article-title":"Cytoreductive surgery combined with perioperative intraperitoneal chemotherapy for the management of peritoneal carcinomatosis from colorectal cancer: a multi-institutional study","volume":"22","author":"Glehen","year":"2004","journal-title":"J\u00a0Clin Oncol \u2013 Off J Am Soc Clin Oncol"},{"key":"10.1016\/j.suronc.2014.03.004_bib37","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1200\/JCO.2009.23.9285","article-title":"Peritoneal colorectal carcinomatosis treated with surgery and perioperative intraperitoneal chemotherapy: retrospective analysis of 523 patients from a multicentric French study","volume":"28","author":"Elias","year":"2010","journal-title":"J\u00a0Clin Oncol \u2013 Off J Am Soc Clin Oncol"},{"key":"10.1016\/j.suronc.2014.03.004_bib38","doi-asserted-by":"crossref","first-page":"5608","DOI":"10.1002\/cncr.25356","article-title":"Toward curative treatment of peritoneal carcinomatosis from nonovarian origin by cytoreductive surgery combined with perioperative intraperitoneal chemotherapy: a multi-institutional study of 1,290 patients","volume":"116","author":"Glehen","year":"2010","journal-title":"Cancer"},{"key":"10.1016\/j.suronc.2014.03.004_bib39","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1097\/SLA.0b013e3181d9765d","article-title":"A\u00a0comparative study of complete cytoreductive surgery plus intraperitoneal chemotherapy to treat peritoneal dissemination from colon, rectum, small bowel, and nonpseudomyxoma appendix","volume":"251","author":"Elias","year":"2010","journal-title":"Ann Surg"},{"key":"10.1016\/j.suronc.2014.03.004_bib40","doi-asserted-by":"crossref","first-page":"3422","DOI":"10.1245\/s10434-008-0127-4","article-title":"Peritoneal surface disease from colorectal cancer: comparison with the hepatic metastases surgical paradigm in optimally resected patients","volume":"15","author":"Shen","year":"2008","journal-title":"Ann Surg Oncol"},{"key":"10.1016\/j.suronc.2014.03.004_bib41","doi-asserted-by":"crossref","first-page":"878","DOI":"10.1016\/j.jamcollsurg.2006.08.024","article-title":"Analysis of prognostic factors in seventy patients having a complete cytoreduction plus perioperative intraperitoneal chemotherapy for carcinomatosis from colorectal cancer","volume":"203","author":"da Silva","year":"2006","journal-title":"J\u00a0Am Coll Surg"},{"key":"10.1016\/j.suronc.2014.03.004_bib42","doi-asserted-by":"crossref","first-page":"3756","DOI":"10.1002\/cncr.25116","article-title":"Cytoreductive surgery and hyperthermic intraperitoneal chemoperfusion versus systemic chemotherapy alone for colorectal peritoneal carcinomatosis","volume":"116","author":"Franko","year":"2010","journal-title":"Cancer"},{"key":"10.1016\/j.suronc.2014.03.004_bib43","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1097\/01.sla.0000255561.87771.11","article-title":"Iterative cytoreductive surgery associated with hyperthermic intraperitoneal chemotherapy for treatment of peritoneal carcinomatosis of colorectal origin with or without liver metastases","volume":"245","author":"Kianmanesh","year":"2007","journal-title":"Ann Surg"},{"key":"10.1016\/j.suronc.2014.03.004_bib44","doi-asserted-by":"crossref","first-page":"978394","DOI":"10.1155\/2013\/978394","article-title":"Prognostic factors of peritoneal metastases from colorectal cancer following cytoreductive surgery and perioperative chemotherapy","volume":"2013","author":"Yonemura","year":"2013","journal-title":"Sci World J"},{"key":"10.1016\/j.suronc.2014.03.004_bib45","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1200\/JCO.2008.19.7160","article-title":"Complete cytoreductive surgery plus intraperitoneal chemohyperthermia with oxaliplatin for peritoneal carcinomatosis of colorectal origin","volume":"27","author":"Elias","year":"2009","journal-title":"J\u00a0Clin Oncol \u2013 Off J Am Soc Clin Oncol"},{"key":"10.1016\/j.suronc.2014.03.004_bib46","first-page":"509","article-title":"Cytoreductive surgery and intraperitoneal chemotherapy for colorectal peritoneal carcinomatosis: prognosis and treatment of recurrences in a cohort study","volume":"38","author":"Cashin","year":"2012","journal-title":"Eur J Surg Oncol \u2013 J Eur Soc Surg Oncol Br Assoc Surg Oncol"},{"key":"10.1016\/j.suronc.2014.03.004_bib47","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1093\/annonc\/mdr301","article-title":"Intraoperative hyperthermic versus postoperative normothermic intraperitoneal chemotherapy for colonic peritoneal carcinomatosis: a case-control study","volume":"23","author":"Cashin","year":"2012","journal-title":"Ann Oncol \u2013 Off J Eur Soc Med Oncol\/ESMO"},{"key":"10.1016\/j.suronc.2014.03.004_bib48","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1200\/JCO.2011.37.1039","article-title":"Treatment of colorectal peritoneal carcinomatosis with systemic chemotherapy: a pooled analysis of north central cancer treatment group phase III trials N9741 and N9841","volume":"30","author":"Franko","year":"2012","journal-title":"J\u00a0Clin Oncol \u2013 Off J Am Soc Clin Oncol"},{"key":"10.1016\/j.suronc.2014.03.004_bib49","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1016\/j.gassur.2003.12.014","article-title":"Cytoreductive surgery with intraperitoneal hyperthermic chemotherapy for advanced gastric cancer","volume":"8","author":"Hall","year":"2004","journal-title":"J\u00a0Gastrointest Surg"},{"key":"10.1016\/j.suronc.2014.03.004_bib50","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1001\/archsurg.139.1.20","article-title":"Cytoreductive surgery and intraperitoneal chemohyperthermia for peritoneal carcinomatosis arising from gastric cancer","volume":"139","author":"Glehen","year":"2004","journal-title":"Arch Surg"},{"key":"10.1016\/j.suronc.2014.03.004_bib51","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1002\/bjs.4695","article-title":"Treatment of peritoneal dissemination from gastric cancer by peritonectomy and chemohyperthermic peritoneal perfusion","volume":"92","author":"Yonemura","year":"2005","journal-title":"Br J Surg"},{"key":"10.1016\/j.suronc.2014.03.004_bib52","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1245\/s10434-006-9205-7","article-title":"Early postoperative intraperitoneal chemotherapy following cytoreductive surgery in patients with very advanced gastric cancer","volume":"14","author":"Cheong","year":"2007","journal-title":"Ann Surg Oncol"},{"key":"10.1016\/j.suronc.2014.03.004_bib53","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1002\/jso.21519","article-title":"Cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy to treat gastric cancer with ascites and\/or peritoneal carcinomatosis: results from a Chinese center","volume":"101","author":"Yang","year":"2010","journal-title":"J\u00a0Surg Oncol"},{"key":"10.1016\/j.suronc.2014.03.004_bib54","doi-asserted-by":"crossref","first-page":"2370","DOI":"10.1245\/s10434-010-1039-7","article-title":"Peritoneal carcinomatosis from gastric cancer: a multi-institutional study of 159 patients treated by cytoreductive surgery combined with perioperative intraperitoneal chemotherapy","volume":"17","author":"Glehen","year":"2010","journal-title":"Ann Surg Oncol"},{"key":"10.1016\/j.suronc.2014.03.004_bib55","first-page":"661","article-title":"Neoadjuvant treatment of gastric cancer with peritoneal dissemination","volume":"32","author":"Yonemura","year":"2006","journal-title":"Eur J Surg Oncol \u2013 J Eur Soc Surg Oncol Br Assoc Surg Oncol"},{"key":"10.1016\/j.suronc.2014.03.004_bib56","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1093\/annonc\/mdp260","article-title":"Phase II study of weekly intravenous and intraperitoneal paclitaxel combined with S-1 for advanced gastric cancer with peritoneal metastasis","volume":"21","author":"Ishigami","year":"2010","journal-title":"Ann Oncol \u2013 Off J Eur Soc Med Oncol\/ESMO"},{"key":"10.1016\/j.suronc.2014.03.004_bib57","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1002\/jso.22057","article-title":"Intraperitoneal docetaxel combined with S-1 for advanced gastric cancer with peritoneal dissemination","volume":"105","author":"Fujiwara","year":"2012","journal-title":"J\u00a0Surg Oncol"},{"key":"10.1016\/j.suronc.2014.03.004_bib58","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.1007\/s00280-013-2122-0","article-title":"Phase I\/II study of intraperitoneal docetaxel plus S-1 for the gastric cancer patients with peritoneal carcinomatosis","volume":"71","author":"Fushida","year":"2013","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1016\/j.suronc.2014.03.004_bib59","doi-asserted-by":"crossref","first-page":"3354","DOI":"10.1002\/cncr.28204","article-title":"A\u00a0phase 2 trial of intravenous and intraperitoneal paclitaxel combined with S-1 for treatment of gastric cancer with macroscopic peritoneal metastasis","volume":"119","author":"Yamaguchi","year":"2013","journal-title":"Cancer"},{"key":"10.1016\/j.suronc.2014.03.004_bib60","doi-asserted-by":"crossref","first-page":"1004","DOI":"10.1056\/NEJM199504133321507","article-title":"Paclitaxel (taxol)","volume":"332","author":"Rowinsky","year":"1995","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.suronc.2014.03.004_bib61","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/S0378-5173(01)00986-3","article-title":"Paclitaxel and its formulations","volume":"235","author":"Singla","year":"2002","journal-title":"Int J Pharm"},{"key":"10.1016\/j.suronc.2014.03.004_bib62","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1016\/j.jss.2008.06.049","article-title":"Different tissue distribution of paclitaxel with intravenous and intraperitoneal administration","volume":"155","author":"Soma","year":"2009","journal-title":"J\u00a0Surg Res"},{"key":"10.1016\/j.suronc.2014.03.004_bib63","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1159\/000209277","article-title":"Phase I pharmacokinetic study of weekly intravenous and intraperitoneal paclitaxel combined with S-1 for advanced gastric cancer","volume":"76","author":"Ishigami","year":"2009","journal-title":"Oncology"},{"issue":"2","key":"10.1016\/j.suronc.2014.03.004_bib64","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1245\/s10434-013-3208-y","article-title":"Salvage gastrectomy after intravenous and intraperitoneal paclitaxel (PTX) administration with oral S-1 for peritoneal dissemination of advanced gastric cancer with malignant ascites","volume":"21","author":"Kitayama","year":"2014","journal-title":"Ann Surg Oncol"},{"key":"10.1016\/j.suronc.2014.03.004_bib65","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/S1470-2045(08)70035-4","article-title":"S-1 plus cisplatin versus S-1 alone for first-line treatment of advanced gastric cancer (SPIRITS trial): a phase III trial","volume":"9","author":"Koizumi","year":"2008","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.suronc.2014.03.004_bib66","first-page":"H26","article-title":"Peritoneal absorption of macromolecules studied by quantitative autoradiography","volume":"248","author":"Flessner","year":"1985","journal-title":"Am J Physiol"},{"key":"10.1016\/j.suronc.2014.03.004_bib67","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1002\/ar.21101","article-title":"Recent advances in the research of lymphatic stomata","volume":"293","author":"Wang","year":"2010","journal-title":"Anat Rec (Hoboken)"},{"key":"10.1016\/j.suronc.2014.03.004_bib68","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1038\/nrclinonc.2009.217","article-title":"Intraperitoneal therapy for peritoneal tumors: biophysics and clinical evidence","volume":"7","author":"Ceelen","year":"2010","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.suronc.2014.03.004_bib69","doi-asserted-by":"crossref","first-page":"109","DOI":"10.4251\/wjgo.v2.i2.109","article-title":"A\u00a0pharmacological review on intraperitoneal chemotherapy for peritoneal malignancy","volume":"2","author":"Yan","year":"2010","journal-title":"World J Gastrointest Oncol"},{"key":"10.1016\/j.suronc.2014.03.004_bib70","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1016\/j.ygyno.2006.02.029","article-title":"A\u00a0phase I trial of intraperitoneal sustained-release paclitaxel microspheres (Paclimer) in recurrent ovarian cancer: a Gynecologic Oncology Group study","volume":"103","author":"Armstrong","year":"2006","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.suronc.2014.03.004_bib71","doi-asserted-by":"crossref","first-page":"3726","DOI":"10.1245\/s10434-011-1770-8","article-title":"Neoadjuvant intraperitoneal and systemic chemotherapy for gastric cancer patients with peritoneal dissemination","volume":"18","author":"Fujiwara","year":"2011","journal-title":"Ann Surg Oncol"},{"key":"10.1016\/j.suronc.2014.03.004_bib72","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1093\/oxfordjournals.annonc.a058883","article-title":"Phase II trial of docetaxel (Taxotere) in metastatic colorectal carcinoma","volume":"5","author":"Pazdur","year":"1994","journal-title":"Ann Oncol \u2013 Off J Eur Soc Med Oncol\/ESMO"},{"key":"10.1016\/j.suronc.2014.03.004_bib73","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1038\/bjc.1994.309","article-title":"Docetaxel (Taxotere), a novel taxoid, in the treatment of advanced colorectal carcinoma: an EORTC Early Clinical Trials Group Study","volume":"70","author":"Sternberg","year":"1994","journal-title":"Br J Cancer"},{"key":"10.1016\/j.suronc.2014.03.004_bib74","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1097\/00045391-199611000-00003","article-title":"Phase II trial of paclitaxel in patients with advanced Colon Cancer previously Untreated with cytotoxic chemotherapy: an Eastern Cooperative Oncology group trial (PA286)","volume":"3","author":"Einzig","year":"1996","journal-title":"Am J Ther"},{"key":"10.1016\/j.suronc.2014.03.004_bib75","first-page":"1793","article-title":"Intraperitoneal treatment using taxol is effective for experimental peritoneal carcinomatosis in a rat model","volume":"10","author":"Hribaschek","year":"2003","journal-title":"Oncol Rep"},{"key":"10.1016\/j.suronc.2014.03.004_bib76","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1159\/000110005","article-title":"Comparison of intraperitoneal with intravenous administration of taxol in experimental peritoneal carcinomatosis","volume":"53","author":"Hribaschek","year":"2007","journal-title":"Chemotherapy"},{"key":"10.1016\/j.suronc.2014.03.004_bib77","doi-asserted-by":"crossref","first-page":"68","DOI":"10.4251\/wjgo.v2.i2.68","article-title":"Hyperthermic intraperitoneal chemotherapy: rationale and technique","volume":"2","author":"Gonzalez-Moreno","year":"2010","journal-title":"World J Gastrointest Oncol"},{"key":"10.1016\/j.suronc.2014.03.004_bib78","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1080\/00015458.2004.11679577","article-title":"Rationale for hyperthermic intraperitoneal chemotherapy (HIPEC) in the treatment or prevention of peritoneal carcinomatosis","volume":"104","author":"Detroz","year":"2004","journal-title":"Acta Chir Belg"},{"key":"10.1016\/j.suronc.2014.03.004_bib79","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1245\/s10434-006-9167-9","article-title":"Comparison of two kinds of intraperitoneal chemotherapy following complete cytoreductive surgery of colorectal peritoneal carcinomatosis","volume":"14","author":"Elias","year":"2007","journal-title":"Ann Surg Oncol"},{"key":"10.1016\/j.suronc.2014.03.004_bib80","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.1517\/14712598.2010.504706","article-title":"Catumaxomab\u2013trifunctional anti-EpCAM antibody used to treat malignant ascites","volume":"10","author":"Bokemeyer","year":"2010","journal-title":"Expert Opin Biol Ther"},{"key":"10.1016\/j.suronc.2014.03.004_bib81","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1177\/002215540104900711","article-title":"Lysis of prostate carcinoma cells by trifunctional bispecific antibodies (alpha EpCAM x alpha CD3)","volume":"49","author":"Riesenberg","year":"2001","journal-title":"J\u00a0Histochem Cytochem"},{"key":"10.1016\/j.suronc.2014.03.004_bib82","first-page":"841","article-title":"Opsonization with a trifunctional bispecific (alphaCD3 x alphaEpCAM) antibody results in efficient lysis in\u00a0vitro and in\u00a0vivo of EpCAM positive tumor cells by cytotoxic T lymphocytes","volume":"25","author":"Schmitt","year":"2004","journal-title":"Int J Oncol"},{"key":"10.1016\/j.suronc.2014.03.004_bib83","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1038\/sj.bjc.6603881","article-title":"Characterisation of the new EpCAM-specific antibody HO-3: implications for trifunctional antibody immunotherapy of cancer","volume":"97","author":"Ruf","year":"2007","journal-title":"Br J Cancer"},{"key":"10.1016\/j.suronc.2014.03.004_bib84","doi-asserted-by":"crossref","first-page":"1387","DOI":"10.2217\/fon.10.111","article-title":"The trifunctional antibody catumaxomab in treatment of malignant ascites and peritoneal carcinomatosis","volume":"6","author":"Strohlein","year":"2010","journal-title":"Future Oncol"},{"key":"10.1016\/j.suronc.2014.03.004_bib85","doi-asserted-by":"crossref","first-page":"1979","DOI":"10.1093\/annonc\/mds178","article-title":"Deterioration in quality of life (QoL) in patients with malignant ascites: results from a phase II\/III study comparing paracentesis plus catumaxomab with paracentesis alone","volume":"23","author":"Wimberger","year":"2012","journal-title":"Ann Oncol \u2013 Off J Eur Soc Med Oncol\/ESMO"},{"key":"10.1016\/j.suronc.2014.03.004_bib86","doi-asserted-by":"crossref","first-page":"2335","DOI":"10.1056\/NEJMoa032691","article-title":"Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer","volume":"350","author":"Hurwitz","year":"2004","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.suronc.2014.03.004_bib87","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1007\/s10434-999-0373-0","article-title":"Markedly elevated levels of vascular endothelial growth factor in malignant ascites","volume":"6","author":"Zebrowski","year":"1999","journal-title":"Ann Surg Oncol"},{"key":"10.1016\/j.suronc.2014.03.004_bib88","doi-asserted-by":"crossref","first-page":"1242","DOI":"10.1634\/theoncologist.2009-0109","article-title":"Intraperitoneal VEGF inhibition using bevacizumab: a potential approach for the symptomatic treatment of malignant ascites?","volume":"14","author":"Kobold","year":"2009","journal-title":"Oncologist"},{"key":"10.1016\/j.suronc.2014.03.004_bib89","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1007\/s00280-009-1219-y","article-title":"Biodistribution of humanized anti-VEGF monoclonal antibody\/bevacizumab on peritoneal metastatic models with subcutaneous xenograft of gastric cancer in mice","volume":"66","author":"Yagi","year":"2010","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1016\/j.suronc.2014.03.004_bib90","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1007\/s00280-011-1566-3","article-title":"Evaluation of combined bevacizumab and intraperitoneal carboplatin or paclitaxel therapy in a mouse model of ovarian cancer","volume":"68","author":"Shah","year":"2011","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1016\/j.suronc.2014.03.004_bib91","first-page":"6387","article-title":"A\u00a0new concept for macromolecular therapeutics in cancer chemotherapy: mechanism of tumoritropic accumulation of proteins and the antitumor agent smancs","volume":"46","author":"Matsumura","year":"1986","journal-title":"Cancer Res"},{"key":"10.1016\/j.suronc.2014.03.004_bib92","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/S0168-3659(99)00248-5","article-title":"Tumor vascular permeability and the EPR effect in macromolecular therapeutics: a review","volume":"65","author":"Maeda","year":"2000","journal-title":"J\u00a0Control Release"},{"key":"10.1016\/j.suronc.2014.03.004_bib93","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1038\/nnano.2007.387","article-title":"Nanocarriers as an emerging platform for cancer therapy","volume":"2","author":"Peer","year":"2007","journal-title":"Nat Nanotechnol"},{"key":"10.1016\/j.suronc.2014.03.004_bib94","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1038\/nrd2614","article-title":"Nanoparticle therapeutics: an emerging treatment modality for cancer","volume":"7","author":"Davis","year":"2008","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.suronc.2014.03.004_bib95","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1111\/j.1349-7006.2009.01103.x","article-title":"Preclinical and clinical studies of anticancer agent-incorporating polymer micelles","volume":"100","author":"Matsumura","year":"2009","journal-title":"Cancer Sci"},{"key":"10.1016\/j.suronc.2014.03.004_bib96","doi-asserted-by":"crossref","first-page":"7794","DOI":"10.1200\/JCO.2005.04.937","article-title":"Phase III trial of nanoparticle albumin-bound paclitaxel compared with polyethylated castor oil-based paclitaxel in women with breast cancer","volume":"23","author":"Gradishar","year":"2005","journal-title":"J\u00a0Clin Oncol \u2013 Off J Am Soc Clin Oncol"},{"key":"10.1016\/j.suronc.2014.03.004_bib97","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1517\/14656561003796562","article-title":"Targeted delivery for breast cancer therapy: the history of nanoparticle-albumin-bound paclitaxel","volume":"11","author":"Petrelli","year":"2010","journal-title":"Expert Opin Pharmacother"},{"key":"10.1016\/j.suronc.2014.03.004_bib98","doi-asserted-by":"crossref","first-page":"1240","DOI":"10.1038\/sj.bjc.6602479","article-title":"NK105, a paclitaxel-incorporating micellar nanoparticle formulation, can extend in\u00a0vivo antitumour activity and reduce the neurotoxicity of paclitaxel","volume":"92","author":"Hamaguchi","year":"2005","journal-title":"Br J Cancer"},{"key":"10.1016\/j.suronc.2014.03.004_bib99","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.1007\/s00280-010-1422-x","article-title":"A\u00a0phase II study of paclitaxel by weekly 1-h infusion for advanced or recurrent esophageal cancer in patients who had previously received platinum-based chemotherapy","volume":"67","author":"Kato","year":"2011","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1016\/j.suronc.2014.03.004_bib100","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1002\/jbm.a.10481","article-title":"Enhanced solubility of paclitaxel using water-soluble and biocompatible 2-methacryloyloxyethyl phosphorylcholine polymers","volume":"65","author":"Konno","year":"2003","journal-title":"J\u00a0Biomed Mater Res A"},{"key":"10.1016\/j.suronc.2014.03.004_bib101","doi-asserted-by":"crossref","first-page":"1979","DOI":"10.1111\/j.1349-7006.2009.01265.x","article-title":"Intraperitoneal administration of paclitaxel solubilized with poly(2-methacryloxyethyl phosphorylcholine-co n-butyl methacrylate) for peritoneal dissemination of gastric cancer","volume":"100","author":"Soma","year":"2009","journal-title":"Cancer Sci"},{"key":"10.1016\/j.suronc.2014.03.004_bib102","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1111\/j.1349-7006.2010.01747.x","article-title":"Spatial distribution of intraperitoneally administrated paclitaxel nanoparticles solubilized with poly (2-methacryloxyethyl phosphorylcholine-co n-butyl methacrylate) in peritoneal metastatic nodules","volume":"102","author":"Kamei","year":"2011","journal-title":"Cancer Sci"},{"key":"10.1016\/j.suronc.2014.03.004_bib103","doi-asserted-by":"crossref","first-page":"1304","DOI":"10.1111\/j.1349-7006.2012.02274.x","article-title":"Antitumor effect and pharmacokinetics of intraperitoneal NK105, a nanomicellar paclitaxel formulation for peritoneal dissemination","volume":"103","author":"Emoto","year":"2012","journal-title":"Cancer Sci"},{"key":"10.1016\/j.suronc.2014.03.004_bib104","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1093\/jnci\/89.7.480","article-title":"Pharmacokinetic problems in peritoneal drug administration: tissue penetration and surface exposure","volume":"89","author":"Dedrick","year":"1997","journal-title":"J\u00a0Natl Cancer Inst"},{"key":"10.1016\/j.suronc.2014.03.004_bib105","first-page":"156","article-title":"Intraperitoneal drug delivery for ovarian cancer: why, how, who, what, and when?","volume":"25","author":"Echarri Gonzalez","year":"2011","journal-title":"Oncol (Williston Park)"},{"key":"10.1016\/j.suronc.2014.03.004_bib106","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1080\/107175401300002694","article-title":"Fluid dynamics in man of an intraperitoneal drug delivery solution: 4% icodextrin","volume":"8","author":"Hosie","year":"2001","journal-title":"Drug Deliv"},{"key":"10.1016\/j.suronc.2014.03.004_bib107","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1007\/s00280-003-0680-2","article-title":"Pharmacokinetics and tissue distribution of intraperitoneal paclitaxel with different carrier solutions","volume":"52","author":"Mohamed","year":"2003","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1016\/j.suronc.2014.03.004_bib108","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1016\/j.canlet.2008.07.024","article-title":"Intra-peritoneal administration of paclitaxel with non-animal stabilized hyaluronic acid as a vehicle\u2013a new strategy against peritoneal dissemination of gastric cancer","volume":"272","author":"Yamada","year":"2008","journal-title":"Cancer Lett"},{"key":"10.1016\/j.suronc.2014.03.004_bib109","doi-asserted-by":"crossref","first-page":"4698","DOI":"10.1016\/j.biomaterials.2006.04.043","article-title":"In situ cross-linkable hyaluronic acid hydrogels prevent post-operative abdominal adhesions in a rabbit model","volume":"27","author":"Yeo","year":"2006","journal-title":"Biomaterials"},{"key":"10.1016\/j.suronc.2014.03.004_bib110","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1016\/j.biomaterials.2006.10.021","article-title":"The prevention of peritoneal adhesions by in situ cross-linking hydrogels of hyaluronic acid and cellulose derivatives","volume":"28","author":"Ito","year":"2007","journal-title":"Biomaterials"},{"key":"10.1016\/j.suronc.2014.03.004_bib111","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1016\/S0169-409X(01)00203-4","article-title":"Environment-sensitive hydrogels for drug delivery","volume":"53","author":"Qiu","year":"2001","journal-title":"Adv Drug Deliv Rev"},{"key":"10.1016\/j.suronc.2014.03.004_bib112","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1007\/s10637-009-9253-5","article-title":"Suppression of in\u00a0vivo tumor growth by using a biodegradable thermosensitive hydrogel polymer containing chemotherapeutic agent","volume":"28","author":"Kwak","year":"2010","journal-title":"Invest New Drugs"},{"key":"10.1016\/j.suronc.2014.03.004_bib113","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/j.ijpharm.2011.06.015","article-title":"Drug release behaviors of a pH sensitive semi-interpenetrating polymer network hydrogel composed of poly(vinyl alcohol) and star poly[2-(dimethylamino)ethyl methacrylate]","volume":"416","author":"Wu","year":"2011","journal-title":"Int J Pharm"},{"key":"10.1016\/j.suronc.2014.03.004_bib114","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/j.jconrel.2008.01.005","article-title":"In situ gelling stimuli-sensitive block copolymer hydrogels for drug delivery","volume":"127","author":"He","year":"2008","journal-title":"J\u00a0Control Release"},{"key":"10.1016\/j.suronc.2014.03.004_bib115","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/S0168-3659(00)00300-X","article-title":"Cross-linked hyaluronic acid hydrogel films: new biomaterials for drug delivery","volume":"69","author":"Luo","year":"2000","journal-title":"J\u00a0Control Release"},{"key":"10.1016\/j.suronc.2014.03.004_bib116","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1186\/1471-2407-10-402","article-title":"5-FU-hydrogel inhibits colorectal peritoneal carcinomatosis and tumor growth in mice","volume":"10","author":"Wang","year":"2010","journal-title":"BMC Cancer"},{"key":"10.1016\/j.suronc.2014.03.004_bib117","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s10637-010-9499-y","article-title":"The antitumor effect of a thermosensitive polymeric hydrogel containing paclitaxel in a peritoneal carcinomatosis model","volume":"30","author":"Yu","year":"2012","journal-title":"Invest New Drugs"},{"key":"10.1016\/j.suronc.2014.03.004_bib118","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1016\/j.jconrel.2011.12.001","article-title":"Hyaluronic acid-based hydrogel for regional delivery of paclitaxel to intraperitoneal tumors","volume":"158","author":"Bajaj","year":"2012","journal-title":"J\u00a0Control Release"},{"key":"10.1016\/j.suronc.2014.03.004_bib119","article-title":"Intraperitoneal administration of cisplatin via an in situ cross-linkable hyaluronic acid-based hydrogel for peritoneal dissemination of gastric cancer","author":"Emoto","year":"2013","journal-title":"Surg Today"},{"key":"10.1016\/j.suronc.2014.03.004_bib120","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1021\/bm000283n","article-title":"A\u00a0hyaluronic acid-taxol antitumor bioconjugate targeted to cancer cells","volume":"1","author":"Luo","year":"2000","journal-title":"Biomacromolecules"},{"key":"10.1016\/j.suronc.2014.03.004_bib121","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1593\/neo.07229","article-title":"Hyaluronic acid-paclitaxel: antitumor efficacy against CD44(+) human ovarian carcinoma xenografts","volume":"9","author":"Auzenne","year":"2007","journal-title":"Neoplasia"},{"key":"10.1016\/j.suronc.2014.03.004_bib122","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1038\/nrc1893","article-title":"Drug penetration in solid tumours","volume":"6","author":"Minchinton","year":"2006","journal-title":"Nat Rev Cancer"}],"container-title":["Surgical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0960740414000279?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0960740414000279?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,18]],"date-time":"2025-10-18T03:15:35Z","timestamp":1760757335000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0960740414000279"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,6]]},"references-count":122,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2014,6]]}},"alternative-id":["S0960740414000279"],"URL":"https:\/\/doi.org\/10.1016\/j.suronc.2014.03.004","relation":{},"ISSN":["0960-7404"],"issn-type":[{"value":"0960-7404","type":"print"}],"subject":[],"published":{"date-parts":[[2014,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Intraperitoneal chemotherapy against peritoneal carcinomatosis","name":"articletitle","label":"Article Title"},{"value":"Surgical Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.suronc.2014.03.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}